JDNPPA is the only independent, omni-channel resource that is for dermatology NPs and PAs and by NPs and PAs.
Joined March 2024
- Tweets965
- Following294
- Followers41
- Likes1.1K
JDNPPA retweeted
#Dermatology PA, Kara Mudd, DMSc, MSPAS, PA-C shares more about her role on the Advisory Council for Maui Derm, and gives insight into why PAs and NPs should join her at the next #MauiDerm meeting in Summer 2027!
JDNPPA retweeted
The US FDA approved remibrutinib (#Rhapsido, @NovartisCT) for adults with symptomatic #dermographism (SD) inadequately controlled by H1 antihistamines. Remibrutinib, an oral, highly selective Bruton’s tyrosine kinase inhibitor (BTKi), is the first and only treatment for adults with SD. jdnppa.com/us-fda-approves-f…
JDNPPA retweeted
The advent of novel non-steroidal targeted topicals, including ruxolitinib cream, have expanded the therapeutic toolbox, providing more options for #atopicdermatitis patients who don’t want to or can’t use topical corticosteroids. tdd.mydigitalpublication.com…
JDNPPA retweeted
Oral icotrokinra (#Icotyde, JNJ) produces durable skin clearance on high-impact #plaquepsoriasis (PsO) sites, new research shows. jdnppa.com/oral-icotrokinra-…
JDNPPA retweeted
Oral Janus kinase (JAK) inhibitors should be first-line therapy for adults with severe #alopecia areata, according to the first-ever standardized treatment recommendations for these patients. jdnppa.com/its-time-to-rethi…
JDNPPA retweeted
The US FDA has approved pritelivir (#Hovilpri, Asahi Kasei Therapeutics) tablets for immunocompromised adults with mucocutaneous lesions caused by #herpessimplex virus (#HSV) infection who have not responded to treatment with acyclovir, valacyclovir, or famciclovir. thedermdigest.com/us-fda-app…
JDNPPA retweeted
The last two episodes in our roundtable series are now available! 📺 Check them out or catch up on all eight episodes released this month! jdnppa.com/videos/refining-t…
JDNPPA retweeted
🆕 🆕 🆕 This broadcast will explore the science behind Cloud-Tech™ & how the Neutrogena® formulation expertise helps optimize both protection & wearability, supporting the features patients want in a daily sunscreen. Register: inceptionmeetings.com/Dermat…
JDNPPA retweeted
From identifying appropriate candidates for #GLP1 RAs to recognizing potential dermatologic complications associated with their use, Laura Bush DMSc, PA-C, DFAAPA, shares practical insights on using these agents in patients with #skindisease and obesity. jdnppa.com/what-every-dermat…
JDNPPA retweeted
Our latest supplement presents summaries of reports on #sarecycline along with clinician commentaries that help apply the findings to patient care. tdd.mydigitalpublication.com…
JDNPPA retweeted
US FDA approves remibrutinib (Rhapsido, @Novartis) for adults with symptomatic #dermographism (SD) inadequately controlled by H1 antihistamines. Remibrutinib, an oral, highly selective Bruton’s tyrosine kinase inhibitor (BTKi), is the first and only treatment for adults with SD. thedermdigest.com/breaking-u…
JDNPPA retweeted
In this new episode of The Blend, Our host, Sonal Choudhary, MD, and Hadar Lev-Tov, MD, discuss advances in #woundcare and healing, including the many ways that regenerative technologies are helping to accelerate healing, improve outcomes, and transform the management of acute and chronic wounds. open.spotify.com/episode/50Z…
JDNPPA retweeted
Today is Chronic Hand Eczema Awareness Day. ✋
Jessica shares how living with chronic hand eczema has made her more mindful of what her hands are exposed to each day: bit.ly/4hmqdXy
#EczemaAwarenessMonth #ChronicHandEczema
Sponsored in part by @LEOHealthySkin
JDNPPA retweeted
[NEW EPISODES] Watch the latest episodes of our newest series on topical JAK inhibition in #atopicdermatitis. thedermdigest.com/videos/ref…
JDNPPA retweeted
Knowing your rheumatology colleagues can help streamline referrals, says Laura Bush DMSc., PA-C, DFAAPA, a Physician Assistant in Fayetteville, GA. Dermatology providers should also recognize the key clinical features of psoriatic arthritis and know how to screen for them. Bush shares practical strategies for strengthening collaboration between #dermatology and #rheumatology to improve the diagnosis and management of diseases with overlapping skin and joint symptoms based on her presentation at the 2026 Science of Skin Summit in Austin, TX. jdnppa.com/enhancing-the-der…
JDNPPA retweeted
[REGISTER NOW] This broadcast will explore the science behind Cloud-Tech™ and how Neutrogena® formulation expertise helps optimize both protection and wearability, supporting the features patients want in a daily sunscreen. Don't miss out! inceptionmeetings.com/Dermat…
JDNPPA retweeted
For Jennifer Hsiao, MD, Director of the #HidradenitisSuppurativa (HS) Clinic at @USC, HS became more than a clinical interest: It became a mission rooted in advocacy and innovation and aimed at improving the lives of patients who have historically been overlooked. Read more: digitaleditions.walsworth.co…
JDNPPA retweeted
Ted Lain, MD, MBA, Co-founder the Science of Skin Summit, discusses the debut of the meeting’s inaugural dedicated NP/PA Track! jdnppa.com/introducing-the-s…
JDNPPA retweeted
In this roundtable discussion, clinicians talk about the growing role that advanced topical therapies such as ruxolitinib (#Opzelura, @Incyte) can, and should, play in #atopicdermatitis (AD). jdnppa.com/videos/refining-t…